In the past week, VRCA stock has gone down by -22.49%, with a monthly decline of -37.02% and a quarterly plunge of -82.99%. The volatility ratio for the week is 24.07%, and the volatility levels for the last 30 days are 11.48% for Verrica Pharmaceuticals Inc The simple moving average for the past 20 days is -24.69% for VRCA’s stock, with a -77.63% simple moving average for the past 200 days.
Is It Worth Investing in Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Right Now?
VRCA has 36-month beta value of 1.45. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRCA is 26.07M, and currently, short sellers hold a 12.48% ratio of that float. The average trading volume of VRCA on October 07, 2024 was 902.75K shares.
VRCA) stock’s latest price update
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) has experienced a decline in its stock price by -9.66 compared to its previous closing price of 1.45. However, the company has seen a fall of -22.49% in its stock price over the last five trading days. globenewswire.com reported 2024-10-02 that – Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure – Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH ® for the treatment of molluscum contagiosum.
Analysts’ Opinion of VRCA
Many brokerage firms have already submitted their reports for VRCA stocks, with Needham repeating the rating for VRCA by listing it as a “Buy.” The predicted price for VRCA in the upcoming period, according to Needham is $10 based on the research report published on July 25, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see VRCA reach a price target of $10. The rating they have provided for VRCA stocks is “Buy” according to the report published on March 22nd, 2023.
RBC Capital Mkts gave a rating of “Outperform” to VRCA, setting the target price at $11 in the report published on February 13th of the previous year.
VRCA Trading at -59.06% from the 50-Day Moving Average
After a stumble in the market that brought VRCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.52% of loss for the given period.
Volatility was left at 11.48%, however, over the last 30 days, the volatility rate increased by 24.07%, as shares sank -31.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -81.93% lower at present.
During the last 5 trading sessions, VRCA fell by -22.49%, which changed the moving average for the period of 200-days by -76.44% in comparison to the 20-day moving average, which settled at $1.7095. In addition, Verrica Pharmaceuticals Inc saw -82.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRCA starting from Hayes Christopher G., who sale 26,183 shares at the price of $2.66 back on Aug 26 ’24. After this action, Hayes Christopher G. now owns 115,303 shares of Verrica Pharmaceuticals Inc, valued at $69,647 using the latest closing price.
Hayes Christopher G., the CHIEF LEGAL OFFICER of Verrica Pharmaceuticals Inc, sale 9,530 shares at $2.46 during a trade that took place back on Aug 27 ’24, which means that Hayes Christopher G. is holding 105,773 shares at $23,444 based on the most recent closing price.
Stock Fundamentals for VRCA
Current profitability levels for the company are sitting at:
- -5.63 for the present operating margin
- 0.84 for the gross margin
The net margin for Verrica Pharmaceuticals Inc stands at -6.25. The total capital return value is set at -2.45. Equity return is now at value -412.98, with -152.23 for asset returns.
Based on Verrica Pharmaceuticals Inc (VRCA), the company’s capital structure generated 1.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.5. The debt to equity ratio resting at -3.29. The interest coverage ratio of the stock is -14.68.
Currently, EBITDA for the company is -62.39 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 5.05. The receivables turnover for the company is 1.36for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.36.
Conclusion
To put it simply, Verrica Pharmaceuticals Inc (VRCA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
